Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1

The WHO 2014 Global tuberculosis report—further to go

(2015) Alimuddin Zumla et al.   Lancet Global Health

The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active against Mycobacterium tuberculosis In Vivo

(2014) Wei Gao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lassomycin, a Ribosomally Synthesized Cyclic Peptide, Kills Mycobacterium tuberculosis by Targeting the ATP-Dependent Protease ClpC1P1P2

(2014) Ekaterina Gavrish et al.   CHEMISTRY & BIOLOGY

Discovery and Characterization of the Tuberculosis Drug Lead Ecumicin

(2014) Wei Gao et al.   ORGANIC LETTERS

Structural Basis of Mycobacterial Inhibition by Cyclomarin A

(2013) Dileep Vasudevan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Advances in the development of new tuberculosis drugs and treatment regimens

(2013) Alimuddin Zumla et al.   NATURE REVIEWS DRUG DISCOVERY

Bacterial proteolytic complexes as therapeutic targets

(2012) Ravikiran M. Raju et al.   NATURE REVIEWS DRUG DISCOVERY

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

(2011) Esther K. Schmitt et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The challenge of new drug discovery for tuberculosis

(2011) Anil Koul et al.   NATURE

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

(2010) Neel R Gandhi et al.   LANCET

Mycobacterium tuberculosis ClpC1

(2008) Narayani P. Kar et al.   FEBS Journal

Biosynthesis and Structures of Cyclomarins and Cyclomarazines, Prenylated Cyclic Peptides of Marine Actinobacterial Origin

(2008) Andrew W. Schultz et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY